Revenue recognized from the Company’s strategic partnerships which includes amounts from Jazz Pharmaceuticals Ireland Limited or Jazz Pharmaceuticals, Inc. (subsidiaries of Jazz Pharmaceuticals plc, collectively referred to as “Jazz”) is summarized as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Jazz:
Development support payments	$	291	$	475	$	683	$	4,968
Drug supply for ongoing studies	791		1,841		1,136		4,798
Other drug supply	45		—		162		2,150
Royalties	1,589		550		2,919		752

BeOne:
Milestone revenue	—		20,000		—		20,000
Recognition of deferred revenue	—		18,334		—		18,334
Drug supply	1,664		7		1,664		215
Royalties	210		19		434		19

Bristol-Myers Squibb company, (“BMS”):
Option exercise fee	—		7,500		—		7,500

GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”):
Milestone revenue	—		—		—		14,000

Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”):
Milestone revenue	—		—		—		3,100
	$	4,590	$	48,726	$	6,998	$	75,836